A new trading day began on Monday, with Apellis Pharmaceuticals Inc (NASDAQ: APLS) stock price down -4.60% from the previous day of trading, before settling in for the closing price of $18.26. APLS’s price has ranged from $16.10 to $42.47 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 20.08% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 2.91%. With a float of $103.43 million, this company’s outstanding shares have now reached $125.66 million.
In an organization with 710 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 82.94%, operating margin of -24.0%, and the pretax margin is -28.66%.
Apellis Pharmaceuticals Inc (APLS) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc is 17.70%, while institutional ownership is 100.06%. The most recent insider transaction that took place on Jun 16 ’25, was worth 93,850. In this transaction General Counsel of this company sold 5,000 shares at a rate of $18.77, taking the stock ownership to the 133,730 shares. Before that another transaction happened on Jun 16 ’25, when Company’s Officer proposed sale 5,000 for $18.77, making the entire transaction worth $93,850.
Apellis Pharmaceuticals Inc (APLS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 2.91% per share during the next fiscal year.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Here are Apellis Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.48 in the next quarter and is forecasted to reach -0.66 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Let’s dig in a bit further. During the last 5-days, its volume was 1.88 million. That was inferior than the volume of 2.2 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 52.20%.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 10.12%, which indicates a significant decrease from 16.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.87% in the past 14 days, which was lower than the 52.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.14, while its 200-day Moving Average is $25.62. However, in the short run, Apellis Pharmaceuticals Inc’s stock first resistance to watch stands at $17.99. Second resistance stands at $18.55. The third major resistance level sits at $18.87. If the price goes on to break the first support level at $17.10, it is likely to go to the next support level at $16.78. The third support level lies at $16.22 if the price breaches the second support level.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
With a market capitalization of 2.19 billion, the company has a total of 125,682K Shares Outstanding. Currently, annual sales are 781,370 K while annual income is -197,880 K. The company’s previous quarter sales were 166,800 K while its latest quarter income was -92,230 K.
